Frank Behrens, MD, PhD

Goethe-University & Fraunhofer ITMP
Frankfurt, Germany

Rheumatologist

Presentation(s):

• 1435: Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients with Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 1 Trial

  Monday, November 13, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.